Shots:
- The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer
- Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study results in R/R FL, that showed 51.6% of patients achieved a CR when treated with mosunetuzumab
- Beyond r/r setting, mosunetuzumab & glofitamab are also being evaluated in 1L DLBCL. Additionally, Roche has presented the data of cevostamab that showed a 53% ORR rate in heavily pre-treated patients with MM
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Financial Times
The post Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020 first appeared on PharmaShots.
